Biologics Testing and Characterization Services
Viral clearance, cell line, impurity-control, microbial, release, and QC support for mAbs, recombinant proteins, biosimilars, and related biologics.
Program Overview
Biologics programs require controlled testing strategies for viral safety, production-cell qualification, host-cell impurities, microbial safety, process residues, and later-stage release support. HyQure supports monoclonal antibodies, recombinant proteins, biosimilars, ADC-associated biologics processes, and bispecific or trispecific antibody programs through viral clearance or inactivation validation, cell line characterization, residual DNA/HCP/HCD-related support, microbial testing, and release-facing documentation.
Why HyQure - Advantages
-
Viral clearance and inactivation support
Process-specific study design and execution for viral clearance or inactivation steps relevant to biologics and selected vaccine or ADC-associated workflows. -
Production cell-line and bank qualification
Cell line characterization, sterility, mycoplasma, adventitious-agent, and genetic-stability support for CHO, HEK293/293, SF9, Vero, and other relevant substrates. -
Impurity and process-residue control
Host-cell residual DNA, HCP/HCD-related support, process-residue testing, and QC kits should be the core impurity story on this page. -
Lot release and commercialization-facing QC
Later-stage lot-release pathways, microbial safety testing, quality documentation, and method-transfer or lifecycle support are presented with disciplined regulatory wording.
Core Biologics Support Capabilities
-
Viral clearance / inactivation validationStudy design, indicator-virus strategy, and process-step evaluation for biologics manufacturing workflows. -
Cell line characterizationIdentity, sterility, mycoplasma, adventitious-agent, retrovirus-related, and genetic-stability testing for production cell substrates.
-
Process residue and host-cell impurity testingResidual DNA, HCP/HCD-related support, QC kits, and related impurity-control pathways for biologics manufacturing and release.
-
Microbial, lot release, and QC supportMicrobiological testing, mycoplasma, endotoxin support, and lot-release documentation for clinical and commercialization-related stages.
Sample Types and Deliverables
Sample types
Production cell banks, process intermediates, viral-clearance study materials, bulk drug substance, and final release-support samples depending on scope.
Program entry points
Biologics, biosimilars, ADC-associated antibody processes, bispecific antibodies, trispecific antibodies, and recombinant proteins.
Key deliverables
Viral-clearance reports, cell-line characterization packages, impurity-test summaries, lot-release support reports, and quality-facing technical documentation.
Program alignment
Broader analytical requests should be confirmed separately when they extend beyond HyQure's supported biosafety, impurity, and QC-support scope.
Regulatory Relevance
For biologics programs, this testing scope supports regulatory-facing documentation for viral clearance or inactivation, cell-line qualification, host-cell impurity control, microbial testing, release support, and commercialization-facing QC workflows. For broader quality context, see Quality & Compliance, Quality Management System (QMS), Regulatory Alignment & Guidelines, Certifications & Accreditations, and Data Integrity & Digital Systems.
CONNECTED CAPABILITIES
Scope Your Project
Connect with our scientific project managers to
define your analytical requirements and
timeline.
Contact Usdefine your analytical requirements and
timeline.